SEC Form 4 · accession 0001104659-26-079793
Nuvectis Pharma, Inc. · NVCT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Marlio Charles Mosseri
10% Owner
Period of report
Jun 30, 2026
Accepted (ET)
Jul 1, 2026 · 1:41 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001875558
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jun 30, 2026 | P | 50,000 | $18.32 | A | 3,186,576 | I | By Emerald Hill Ventures SARL SPF. |
| Common Stock | holding | — | — | — | 109,321 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Reflects the weighted average purchase price. The range of prices for the shares purchased was $18.29 to $18.32. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price.
- F2Charles Mosseri Marlio is the beneficial owner of Emerald Hill Ventures SARL SPF.